BD shares fall by 3% after lowering FY26 profit outlook

Becton Dickinson and Company (BD) has trimmed its fiscal twelvemonth 2026 (FY26) nett outlook to relationship for the spin-off of its biosciences & diagnostic solutions business, prompting its stock terms to autumn by 3%.

BD reached a $17.5bn statement to merge the portion with Waters, a laboratory instrumentality maker, successful July 2025 and announced the deal’s ceremonial completion alongside its Q1 2026 financials, released up of marketplace unfastened connected 9 February.

Due to the completed transaction with Waters, BD said it present expects FY26 net per stock (EPS) to autumn successful the $12.35 to $12.65 per stock range, down from $14.75 to $15.05 arsenic antecedently mooted successful the company’s FY25 results, released successful November 2025.

The accommodation prompted BD’s shares connected the New York Stock Exchange (NYSE) to autumn by astir 3% to $204 per stock astatine marketplace unfastened connected 9 February, down from $210.02 astatine marketplace adjacent connected the time prior. BD has a marketplace headdress of $59.09bn.

Despite the marketplace response, BD CEO Tom Polen said successful a connection that the company’s Q1 FY2026 results were “stronger than expected.”

BD achieved profits of $5.25bn successful the quarter, corresponding to a 1.6% emergence connected Q1 FY2025. Medical essentials was the strongest performing vertical astatine $1.60bn, though it was the weakest maturation country astatine conscionable 0.6% maturation versus Q1 FY2025. The different strongest performing verticals for BD were interventional and connected attraction astatine $1.33bn and $1.13bn, respectively.

Meanwhile, BD interventional represented the biggest maturation vertical versus Q1 FY2025 astatine 5.8%, followed by connected attraction and biopharma systems with maturation of 5.5% and 2.7%, respectively.

Polen commented: “We delivered stronger‑than‑expected first‑quarter show which reflects our disciplined execution, including accelerated commercialized initiatives and broad‑based maturation crossed cardinal extremity markets.”

Reflecting connected the completion of the transaction with Waters, Polen continued: "With this important milestone successful our strategy to thrust shareholder value, we afloat pivot to New BD and the adjacent section of the company's growth.”

Boston Scientific besides experienced a autumn successful its banal terms aft releasing its 2025 financials. The medtech giant's shares fell by 18% aft releasing its net up of marketplace unfastened connected 4 February, with investors homing successful connected comparatively level income wrong the company's electrophysiology (EP) and Watchman segments that correspond 2 of its cardinal gross drivers.

"BD shares autumn by 3% aft lowering FY26 nett outlook" was primitively created and published by Medical Device Network, a GlobalData owned brand.